Udenyca Onbody Market Share Surges: How Coherus Shakes Up The Pegfilgrastim Landscape In 2026
The biotechnology sector is witnessing a major shift in the supportive cancer care market as Coherus BioSciences continues to capture significant market share with UDENYCA ONBODY® (pegfilgrastim-cbqv). Operating as a key biosimilar competitor to Amgen's dominant Neulasta Onpro, this innovative on-body injector system has reshaped clinical workflows and patient convenience since its initial commercial rollout. As of August 9, 2026, healthcare providers are increasingly adopting this delivery mechanism to optimize outpatient neutropenia management.
| Metric/Feature | Details |
|---|---|
| Product Name | UDENYCA ONBODY® (pegfilgrastim-cbqv) |
| Manufacturer | Coherus BioSciences, Inc. |
| Therapeutic Class | Leukocyte growth factor (Biosimilar) |
| Primary Indication | Reduction of infection/febrile neutropenia risk in chemotherapy patients |
| Current Market Status | Active commercial distribution (Post-launch expansion) |
Context & Background
For years, Amgen's Neulasta Onpro held a virtual monopoly on the on-body injector market, offering chemotherapy patients a reliable way to receive their necessary pegfilgrastim dose at home without returning to the clinic the day after chemotherapy. That landscape changed dramatically following the FDA approval of UDENYCA ONBODY® in late 2023.
Coherus BioSciences designed UDENYCA ONBODY® to directly challenge this monopoly, completing its three-presentation franchise which also includes a traditional prefilled syringe and an autoinjector. By offering multiple delivery modalities, Coherus has successfully negotiated preferred formulary positioning with major commercial payers and pharmacy benefit managers (PBMs) throughout 2025 and into 2026.
Impact & Utility
The clinical and operational utility of UDENYCA ONBODY® centers on patient autonomy and treatment adherence. Chemotherapy regimens often leave patients highly fatigued and immunocompromised, making return visits to a clinical setting both exhausting and hazardous.
Key benefits driving clinical adoption include:
- Rapid Delivery: Features an efficient 5-minute injection duration, significantly faster than older industry standards.
- Visual and Auditory Indicators: Employs clear status lights and audio cues to confirm successful dose delivery, reducing patient anxiety and preventing dosing errors.
- Economic Value: As a biosimilar, it introduces essential price competition, lowering overall oncology care expenditures for hospitals, insurers, and self-pay patients alike.
DailyMed - UDENYCA- pegfilgrastim-cbqv injection, solution
What's Next
Moving through the second half of 2026, the focus for Coherus BioSciences remains on securing deeper market penetration within major oncology networks and community clinics. With multiple pegfilgrastim biosimilars now competing for market share, manufacturer rebate strategies and supply chain reliability will dictate long-term leadership.
Industry analysts are closely monitoring Coherus' capacity to scale production to meet growing outpatient demand. As digital healthcare integration advances, future updates to the on-body injector category may involve smart-device connectivity, further cementing the role of biosimilars in modern, patient-centric oncology care.
